Nature Communications

Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma

2025-12-14

Full text

DOI https://doi.org/10.1038/s41467-025-67508-8